"U.S. FDA supports an accelerated approval pathway for Rexlemestrocel-L, Mesoblast’s allogeneic mesenchymal precursor cell (MPC) product"
Nope, that was the misleading headline of the announcement from Mesoblast.
The actual detail DIDN'T say that. It said the data MAY support an accelerated approval pathway. In my view, thats quite a different from what the company suggested in the headline they released. But it's had the intended effect of a temporary share price appreciation to get a bit more money in the company's account while giving the short traders a free gift.
"U.S. FDA supports an accelerated approval pathway for...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.10 |
Change
-0.025(2.23%) |
Mkt cap ! $1.250B | |||
| Open | High | Low | Value | Volume |
| $1.13 | $1.16 | $1.04 | $14.57M | 13.49M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 21024 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 241 | 1 |
View Market Depth
| Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |